Clinical trials located in

Bath

Bath city is located in United Kingdom. Currently, 7 clinical trials are being conducted in this city.

Bath, a UNESCO World Heritage city in the United Kingdom, is renowned for its ancient Roman Baths, stunning Georgian architecture, and the historic Bath Abbey. Founded around thermal springs, it has been a wellness destination since Roman times. The city inspired Jane Austen’s novels and boasts the original Sally Lunn’s buns. Bath’s remarkable architecture includes the Royal Crescent, a masterpiece of Georgian design. The city also hosts the annual Bath Literature Festival, celebrating its rich literary heritage.

  • CT-EU-00057394

    Testing brepocitinib medicine’s effect on adult skin and muscle disease

    This study is going to check if a medicine called brepocitinib can help adults with a skin and muscle disease called dermatomyositis. The researchers are making sure that patient results are accurate by giving some people the actual medicine and others a placebo, which has no active substance. The researchers are comparing two different amounts of the medicine against the placebo one to see if the patients get better. It will be tracked by creating a score based on how severe 6 different signs of the disease are, and then tallying up these scores over a period of one year. Those who are part of this one year study can choose to extend their participation for another year, where everyone gets the medicine with active substance. The researchers determine if the patient has improved by looking for an increase in their score of 40 points or more. And also look at how well a person can do their daily tasks, and also score the severity of any skin issues they have at the start and end of the study to check for changes.

    • Brepocitinib
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Testing Treprostinil Palmitil inhalation powder for pulmonary arterial pressure

    This trial is about a new drug called Treprostinil Palmitil Inhalation Powder (TPIP). TPIP is tested on people who have a condition where the blood pressure in the lungs is too high. This condition is called Pulmonary Arterial Hypertension. The objective of this study is to ascertain the effectiveness and safety of TPIP, and to examine its pharmacokinetics, i.e., how it moves within the body. The trial is set up in such a way that some people will get TPIP, while others receive a placebo. The primary focus is on determining whether TPIP can effectively reduce resistance to blood flow within the lungs, constituting a key aspect of the study’s goals.

    • Treprostinil Palmitil
  • Exploring the efficacy and safety of new drug in Psoriasis Treatment

    This clinical trial is for patients suffering from a skin condition called mild to moderate psoriasis. The aim of the study is to check the effectiveness and safety of a new drug called HRO350. HRO350 is a soft capsule containing oil extracted from herring roe (fish roe). This oil contains natural substances called phospholipids, which are rich in certain fatty acids. These substances have the potential to slow or stop the inflammation that causes psoriasis. Patients in the study will take HRO350 capsules or a placebo (a dummy medicine that contains no active substance) every day for up to a year. They will also have an 8-week follow-up period after completing treatment. Approximately 519 patients will participate in the study. The test will involve regular check-ups, including blood and urine tests, and an assessment of the severity of patients’ psoriasis.

    • HRO350- new potential medication for psoriasis
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in United Kingdom:

.